BAY 41-2272 structure
|
Common Name | BAY 41-2272 | ||
|---|---|---|---|---|
| CAS Number | 256376-24-6 | Molecular Weight | 360.388 | |
| Density | 1.5±0.1 g/cm3 | Boiling Point | 496.1±45.0 °C at 760 mmHg | |
| Molecular Formula | C20H17FN6 | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | 253.8±28.7 °C | |
Use of BAY 41-2272BAY 41-2272 is a soluble guanylate cyclases (sGC) activator.Target: guanylate cyclaseBAY 41-2272 is a recently introduced novel orally available agent that directly stimulates soluble guanylate cyclase (sGC) and sensitizes it to its physiological stimulator, nitric oxide. BAY 41-2272 is a promising new therapeutic agent that goes beyond current therapeutic agents. BAY 41-2272 acts as an arterial vasodilator, resulting in a reduction of MAP and pulmonary artery pressure and a decrease in SVR and renal vascular resistance. BAY 41-2272 reduces pulmonary capillary wedge pressure in the absence of a decrease in right atrial pressure. [2] |
| Name | 5-cyclopropyl-2-[1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-4-amine |
|---|---|
| Synonym | More Synonyms |
| Description | BAY 41-2272 is a soluble guanylate cyclases (sGC) activator.Target: guanylate cyclaseBAY 41-2272 is a recently introduced novel orally available agent that directly stimulates soluble guanylate cyclase (sGC) and sensitizes it to its physiological stimulator, nitric oxide. BAY 41-2272 is a promising new therapeutic agent that goes beyond current therapeutic agents. BAY 41-2272 acts as an arterial vasodilator, resulting in a reduction of MAP and pulmonary artery pressure and a decrease in SVR and renal vascular resistance. BAY 41-2272 reduces pulmonary capillary wedge pressure in the absence of a decrease in right atrial pressure. [2] |
|---|---|
| Related Catalog | |
| References |
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Boiling Point | 496.1±45.0 °C at 760 mmHg |
| Molecular Formula | C20H17FN6 |
| Molecular Weight | 360.388 |
| Flash Point | 253.8±28.7 °C |
| Exact Mass | 360.149872 |
| PSA | 83.24000 |
| LogP | 1.99 |
| Vapour Pressure | 0.0±1.3 mmHg at 25°C |
| Index of Refraction | 1.767 |
| Storage condition | -20℃ |
| Precursor 9 | |
|---|---|
| DownStream 0 | |
| 5-Cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-4-pyrimidinamine |
| 5-cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-4-amine |
| 3-(4-Amino-5-cyclopropylpyrimidine-2-yl)-1-(2-fluorobenzyl)-1H-pyrazolo(3,4-b)pyridine |
| bay-41-2272 |
| 4-pyrimidinamine, 5-cyclopropyl-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]- |
| unii-34a162j6wb |
| BAY 41-2272 |